3D Printed Drugs Market Outlook:
According to the research report published by DataM Intelligence, the global 3D Printed Drugs market size was worth USD 294.6 million in 2021 and is estimated to reach USD 558.0 million by 2029, growing at a CAGR of 7.9% during the forecast period 2022-2029.
3D printed drugs are drugs manufactured by solidifying layers of materials to form a definite 3D structure. The adaptability of 3D printing is also applied for the precise and unique dosing of medicines, to present more efficient drug administration. 3D printing is expected to be an efficient method to enhance the application of several controlled drug release mechanisms, during the forecast period.
New players are also entering the market with advanced technology to meet the rising demand, which creates several opportunities in the market over the forecast period. For instance, FabRX, a biotech start-up that specializes in 3D printing medicines, is providing personalized medicines and drug-loaded medical devices through their patented technologies.
3D Printed Drugs Market Growth:
The growing advancements in 3D printing technology is one of the major factor driving the growth of the 3Dprinted drugs market. For instance, in December 2017, Aprecia and Cycle Pharmaceuticals from Cambridge in the UK announced a partnership to develop and commercialize 3D printed tablets for orphan (rare) diseases using the ZipDose technology.
In 2015, the Howard Hughes Medical Institute developed a molecular 3D printer for formulating new drugs by synthesizing blocks of small molecules from the basic chemical pattern.
In addition, the rising investments to increase the research activities for the development of highly efficient 3D printed drugs are expected to boost the growth of the market during the forecast period.
Download Sample Report with Table of Contents @ https://www.datamintelligence.com/download-sample/3d-printed-drugs-market
Despite many potential advantages of 3D printing, expectations are often inflated by the media and even researchers. This promotes unrealistic projections, especially regarding how soon some of the more exciting possibilities—such as organ printing—will become a reality.
In a country like India, 3D printing will need vision, money, and time for the technology to evolve into the anticipated applications. While it is certain that the biomedical sector will be one of the most fertile fields for 3D printing innovations, it is important to appreciate what has already been achieved in another part of the world.
The approval from regulatory authorities is another significant barrier that may impede the market of 3D-printed drugs.
Fulfilling more demanding FDA regulatory requirements could be a hurdle that may impede the availability of 3D-printed drugs on a large scale.
3D printing plays an important role in the trend toward personalized medicine, through its use in customizing nutritional products, organs, and drugs. This would cause existing drug manufacturing and distribution methods to change drastically and become more cost-effective.
An appropriate understanding of the human models of diseases and pharmacodynamics of 3D printed drugs can help deal with the probable side effects of 3D printed drugs and provide us a better choice over traditional drugs.
Proper and controlled use of science and technology can help us achieve all the pros of this 3D printing technology, especially in medical sciences.
Although we can consider that we are still at the early stages of the development of 3D printed drugs, and the official arrival of personalized medicine, we cannot deny that this sector is growing. The companies interviewed agree that we will see changes in our drug consumption within the next decade if the sector continues to grow as it has in the past two years.
The global market is divided into Drug Type, Technology, and End-user.
By Drug Type:
- Inkjet Printing
- Fused deposition modelling
- Research Laboratories
Impact of COVID-19 on the 3D Printed Drugs Industry
The COVID-19 pandemic has caused a dramatic mismatch of supply and demand that manufacturers are struggling to forecast. On the supply side, manufacturing and supply chain processes in hubs such as China, India, and the United States are being disrupted due to global lockdowns.
On the demand side, conflated factors make demand difficult to predict. On one hand, patients delay seeking treatment, particularly for less convenient administration methods such as infusions, which can lead to lower patient volume and overall demand.
On the other hand, stockpiling and demand for subcutaneous or oral formulations may cause a spike in demand for certain products despite decreasing patient volume.
Although all manufacturers are working to mitigate the risk of supply shortages, biosimilar manufacturers that rely on facilities in Europe and Asia may be particularly at risk on the supply side.
Geographical Classification and Regional Insights
The market is divided into major five regions such as North America, Europe, Asia Pacific, Latin America, the Middle East and Africa, and the Rest of the world.
North America 3D Printed Drugs Market
North America has the largest share in the global 3D printed drugs market. The US is the one and only country that has approved the first 3D drug called Spritam (levetiracetam) in the country. It is the first 3D-printed drug to receive approval from the U.S. Food and Drug Administration (FDA) and is now being shipped to pharmacies.
The surge in demand for instantaneous soluble drugs that can disperse easily in the mouth is the major factor that drives the growth of the market in the country. Additionally, many state-of-the-art universities is collaborating with 3D drugs manufacturing companies for the research and development of new pharmaceuticals.
Europe 3D Printed Drugs Market
Europe is a developing market for 3D printed drugs and is expected to account for the second-largest market over the forecast period. Primarily, many German pharmaceutical companies are conducting research and development to manufacturing 3D printed drugs. For instance, a Germany-based Company, 3D Printer Drug Machine, is planning to do so with the creation of a 3D drug printer, and special custom drug delivery polymer filaments.
Many European companies are involved in agreements and collaborations with the US pharmaceutical company Aprecia pharmaceuticals for the development of 3D pharmaceuticals.
Asia Pacific 3D Printed Drugs Market
The Asia Pacific is expected to grow at a high growth rate in the coming years. The growth of the market is due to the increasing research activities, rising prevalence of various diseases such as epilepsy, and growing government initiatives are the major factors that are driving the growth of the market in the region.
For instance, according to WHO, epilepsy affects about 1% of the population of the South-East Asia Region. Approximately 15 million people with epilepsy are only in South-East Asia. These factor has boosted the development of 3D-printed pharmaceutical for the cure of the disease.
Chinese pharmaceutical companies are constantly working on the development of 3D pharmaceuticals. Also, these companies are supported by the government of China.
The Middle East and Africa 3D Printed Drugs Market
Middle East & Africa is considered to provide lucrative opportunities in the forecast period. The increasing prevalence of epilepsy in the region is driving the growth of the market in the forecast period. Currently, there is no any drugs manufacturer in the region, however, there are certain companies such as Dr. Reddy’s, Cipla, and others that are supplying Spritam in the region.
The market for 3D printed pharmaceuticals is growing with major players such as Aprecia Pharmaceuticals, FabRx Ltd., E. Merck KG, and comprising of the major markets players. However, the introduction of Spritam has created lucrative opportunities for the Aprecia Pharmaceuticals, presently it has a monopoly in the market.
Companies are undergoing collaborations and partnerships to develop new products. For instance, in February 2021, GlaxoSmithKline has also shown interest in 3D printing of drugs, partnering with the University of Nottingham on a study that used nozzle printing and ultraviolet curing to produce 3D printed ropinirole tablets to treat Parkinson’s disease.
The key market players are adopting various strategies such as mergers and acquisitions, product approvals, and agreements to increase product reach and strengthen their product portfolios, in order to enter or expand their business offerings and competitiveness in the 3D printed drugs market.
The market for 3D printed pharmaceuticals is growing with major players such as Aprecia Pharmaceuticals, FabRx Ltd., E. Merck KG, and comprising of the major markets players.
Why Purchase the Report?
- Visualize the composition of the 3D printed drugs market segmentation by drug, technology, and end-user highlighting the key commercial assets and players.
- Identify commercial opportunities in the 3D printed drugs market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of 3D printed drugs market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.
Name: Sai Kiran
Company: DataM Intelligence
Contact No: +1 8774414866
Email us: email@example.com